Alcohol-Associated Liver Disease: Epidemiology, Pathogenesis, and Emerging Therapeutic Targets.
- 1Division of Gastroenterology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
Abstract
Alcohol-associated liver disease (ALD) represents a leading cause of preventable liver-related morbidity and mortality worldwide. Despite its growing global burden, no pharmacological therapies targeting disease progression have achieved clinical approval, with management still centered on alcohol abstinence and supportive care. Classic pathogenic mechanisms, including ethanol metabolism, oxidative stress, innate immune activation, and regulated cell death, are well recognized, yet emerging evidence highlights the gut-liver axis and intestinal dysbiosis as critical, interactive drivers of disease pathophysiology. However, how gut microbial imbalance mechanistically intersects with these canonical pathways to accelerate ALD progression remains insufficiently integrated. This article summarizes the epidemiology, clinical manifestations, and pathogenesis of ALD. Importantly, we focus specifically on changes in the gut microbiota (including bacteria, fungi, and viruses) and microbial metabolites. We further discuss the interactive relationships between dysbiosis and these core mechanisms. Finally, we summarize progress in preclinical and clinical research on targeted strategies such as probiotics, fecal microbiota transplantation, and phage therapy. By synthesizing the research findings, we propose a stage-based, mechanism-oriented framework aimed at advancing the development of safer and more precise therapeutic interventions for ALD.
Related
- Sepsis-associated sarcopenia: Emerging insights into mechanisms and therapeutic approaches
- Cancer-associated fibroblasts: multifaceted regulators of the tumor microenvironment and emerging therapeutic targets
- Targeting Gut Microbiota, Inflammation, and Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: Therapeutic Strategies and the Emerging Role of Time-Restricted Feeding
- The gasdermin family in depression-associated neuroinflammation: established evidence, emerging mechanisms, and therapeutic perspectives
- State-of-the-Art Review: Native Joint Septic Arthritis Epidemiology, Pathogenesis, Microbiology, Diagnosis, Management, and Outcomes.
BibTeX
@article{wang2026alcoholassociated,
title = {{Alcohol-Associated Liver Disease: Epidemiology, Pathogenesis, and Emerging Therapeutic Targets.}},
author = {Shuyan Wang and Yirui Hu and Huikuan Chu},
journal = {MedComm},
year = {2026},
month = nov,
doi = {10.1002/mco2.71120},
url = {https://europepmc.org/article/MED/42996894},
note = {CC BY},
}
RIS
TY - JOUR
TI - Alcohol-Associated Liver Disease: Epidemiology, Pathogenesis, and Emerging Therapeutic Targets.
AU - Shuyan Wang
AU - Yirui Hu
AU - Huikuan Chu
PY - 2026
DA - 2026/11/05
JO - MedComm
DO - 10.1002/mco2.71120
UR - https://europepmc.org/article/MED/42996894
AB - Alcohol-associated liver disease (ALD) represents a leading cause of preventable liver-related morbidity and mortality worldwide. Despite its growing global burden, no pharmacological therapies targeting disease progression have achieved clinical approval, with management still centered on alcohol abstinence and supportive care. Classic pathogenic mechanisms, including ethanol metabolism, oxidative stress, innate immune activation, and regulated cell death, are well recognized, yet emerging evidence highlights the gut-liver axis and intestinal dysbiosis as critical, interactive drivers of disease pathophysiology. However, how gut microbial imbalance mechanistically intersects with these canonical pathways to accelerate ALD progression remains insufficiently integrated. This article summarizes the epidemiology, clinical manifestations, and pathogenesis of ALD. Importantly, we focus specifically on changes in the gut microbiota (including bacteria, fungi, and viruses) and microbial metabolites. We further discuss the interactive relationships between dysbiosis and these core mechanisms. Finally, we summarize progress in preclinical and clinical research on targeted strategies such as probiotics, fecal microbiota transplantation, and phage therapy. By synthesizing the research findings, we propose a stage-based, mechanism-oriented framework aimed at advancing the development of safer and more precise therapeutic interventions for ALD.
SN - 2688-2663
ER -